JP2023524811A5 - - Google Patents
Info
- Publication number
- JP2023524811A5 JP2023524811A5 JP2022567556A JP2022567556A JP2023524811A5 JP 2023524811 A5 JP2023524811 A5 JP 2023524811A5 JP 2022567556 A JP2022567556 A JP 2022567556A JP 2022567556 A JP2022567556 A JP 2022567556A JP 2023524811 A5 JP2023524811 A5 JP 2023524811A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- domain
- antigen
- numbers
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020196P | 2020-05-05 | 2020-05-05 | |
| US63/020,196 | 2020-05-05 | ||
| US202063129718P | 2020-12-23 | 2020-12-23 | |
| US63/129,718 | 2020-12-23 | ||
| US202163147618P | 2021-02-09 | 2021-02-09 | |
| US63/147,618 | 2021-02-09 | ||
| US202163171751P | 2021-04-07 | 2021-04-07 | |
| US63/171,751 | 2021-04-07 | ||
| PCT/US2021/030973 WO2021226289A2 (en) | 2020-05-05 | 2021-05-05 | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524811A JP2023524811A (ja) | 2023-06-13 |
| JP2023524811A5 true JP2023524811A5 (https=) | 2024-05-15 |
| JP7796044B2 JP7796044B2 (ja) | 2026-01-08 |
Family
ID=78468785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567556A Active JP7796044B2 (ja) | 2020-05-05 | 2021-05-05 | Ｃｄ７０特異的融合タンパク質を使用したｔｃｒリプログラミングのための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252641A1 (https=) |
| EP (1) | EP4146233A4 (https=) |
| JP (1) | JP7796044B2 (https=) |
| KR (1) | KR20230020421A (https=) |
| CN (1) | CN115989033B (https=) |
| AU (1) | AU2021268953A1 (https=) |
| BR (1) | BR112022022353A2 (https=) |
| CA (1) | CA3177488A1 (https=) |
| IL (1) | IL297916A (https=) |
| MX (1) | MX2022013956A (https=) |
| WO (1) | WO2021226289A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| US20240117002A1 (en) * | 2020-12-23 | 2024-04-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20250255960A1 (en) * | 2022-01-19 | 2025-08-14 | Hrain Biotechnology Co., Ltd. | Anti-cd70 nanoantibody and use thereof |
| WO2023177821A2 (en) * | 2022-03-16 | 2023-09-21 | Myeloid Therapeutics, Inc. | Binding domains and methods of use thereof |
| KR20260018068A (ko) * | 2023-05-26 | 2026-02-06 | 에디타스 메디신, 인코포레이티드 | Cd70 발현을 표적화하는 crispr 관련 방법 및 조성물 |
| CN121299119B (zh) * | 2025-12-15 | 2026-03-06 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 噬血细胞综合征克隆性免疫细胞检测试剂组合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013004792A (es) | 2010-10-27 | 2013-08-27 | Baylor College Medicine | Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas. |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| KR20180075689A (ko) * | 2015-11-23 | 2018-07-04 | 트르스티스 오브 보스톤 유니버시티 | 키메라 항원 수용체에 관한 방법 및 조성물 |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| TWI785009B (zh) | 2017-02-14 | 2022-12-01 | 美商凱特製藥公司 | Ｃｄ７０結合分子及使用彼之方法 |
| WO2019067805A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| GB201800649D0 (en) * | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| CN112020518A (zh) * | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
| CA3111087A1 (en) * | 2018-08-29 | 2020-03-05 | Nanjing Legend Biotech Co., Ltd. | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof |
| US20220054544A1 (en) | 2018-09-21 | 2022-02-24 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
| WO2021133959A2 (en) * | 2019-12-24 | 2021-07-01 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| WO2022006451A2 (en) * | 2020-07-02 | 2022-01-06 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies |
| US20240117002A1 (en) * | 2020-12-23 | 2024-04-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2022150831A1 (en) * | 2021-01-07 | 2022-07-14 | Innovative Cellular Therapeutics Holdings, Ltd. | Car cells and polyspecific binding molecules for treating solid tumor |
| WO2022192286A1 (en) * | 2021-03-09 | 2022-09-15 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and rna interference |
| WO2022232277A1 (en) * | 2021-04-27 | 2022-11-03 | TCR2 Therapeutics Inc. | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH |
-
2021
- 2021-05-05 WO PCT/US2021/030973 patent/WO2021226289A2/en not_active Ceased
- 2021-05-05 US US17/923,008 patent/US20240252641A1/en active Pending
- 2021-05-05 KR KR1020227042681A patent/KR20230020421A/ko not_active Withdrawn
- 2021-05-05 CA CA3177488A patent/CA3177488A1/en active Pending
- 2021-05-05 AU AU2021268953A patent/AU2021268953A1/en active Pending
- 2021-05-05 EP EP21799797.2A patent/EP4146233A4/en active Pending
- 2021-05-05 CN CN202180048074.0A patent/CN115989033B/zh active Active
- 2021-05-05 MX MX2022013956A patent/MX2022013956A/es unknown
- 2021-05-05 JP JP2022567556A patent/JP7796044B2/ja active Active
- 2021-05-05 IL IL297916A patent/IL297916A/en unknown
- 2021-05-05 BR BR112022022353A patent/BR112022022353A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524811A5 (https=) | ||
| US20250092133A1 (en) | Bispecific antibody constructs for cdh3 and cd3 | |
| JP7098629B2 (ja) | 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途 | |
| JP6879998B2 (ja) | Ｃｄ７０及びｃｄ３に対する抗体構築物 | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2021534762A5 (https=) | ||
| JP2021510521A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| JP2019533719A5 (https=) | ||
| JP2022542543A5 (https=) | ||
| AU2016302580A1 (en) | Antibody constructs for FLT3 and CD3 | |
| JP2018502050A5 (https=) | ||
| CA3131036A1 (en) | Cd3 antigen-binding fragment and application thereof | |
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| WO2022152290A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2023511963A5 (https=) | ||
| JP2024515560A5 (https=) | ||
| JP2024535930A5 (https=) | ||
| WO2023241656A1 (zh) | 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途 | |
| WO2019230869A1 (ja) | 抗ヒトｔｌｒ７抗体 | |
| JPWO2011007853A1 (ja) | 癌特異的アイソフォームに対するモノクローナル抗体 | |
| AU2024295542A1 (en) | Anti-fgfr2/pd-1 bispecific antibody |